TransCode Therapeutics Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: TransCode Therapeutics Inc.
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: Delaware
Headquarters city: Boston
Headquarters state / province: Massachusetts
Headquarters country: United States
Fiscal year end: December
Ticker symbol: RNAZ
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001829635
EIN: 81-1065054

Board of directors

Follow this board

Elizabeth Czerepak · Director
Since 2025
Erik Manting · Director
Since 2023
Jack E. Stover · Director
Since 2025
Magda Marquet · Director Overboarded
Since 2023
Philippe Calais · Director
Since 2023
Robert Michael Dudley · Director · Chief Executive Officer
Since 2023
Thomas A. Fitzgerald · Director · Chief Financial Officer
Since 2023

Chief executives

Robert Michael Dudley · Chief Executive Officer

Dates unknown

Thomas A. Fitzgerald · Interim CEO, CFO Interim

Dates unknown

Director election results

Annual meeting of July 20, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

3 of this board's directors also sit on 7 other boards. 7 are in the same sector.

Shared director Other board Same sector

AnaptysBio Inc. Same sector
via Magda Marquet
Arcturus Therapeutics Holdings Inc. Same sector
via Magda Marquet
Delcath Systems Inc. Same sector
via Elizabeth Czerepak
First Tracks Biotherapeutics Inc. Same sector
via Magda Marquet
Immix Biopharma Inc. Same sector
via Magda Marquet
Profusa Inc. Same sector
via Jack E. Stover
Traws Pharma Inc. Same sector
via Jack E. Stover

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $0; 0 sales by 0 insiders

Date	Insider	Transaction	Shares	Price	Value
Aug 3, 2026	CK Life Sciences Intl (Holdings) Inc 10% owner	Derivative conversion	+11,813,859	—	—
Aug 3, 2026	CK Life Sciences Intl (Holdings) Inc 10% owner	Derivative conversion	+2,020,582	—	—
Sep 28, 2023	Thomas A. Fitzgerald Director, Officer (Chief Financial Officer)	Open-market purchase	+49,350	$0.51	$25,169
Sep 28, 2023	Robert Michael Dudley Director, Officer (Chief Executive Officer)	Open-market purchase	+98,000	$0.51	$49,980
Jun 21, 2023	Robert Michael Dudley Director, Officer (Chief Executive Officer)	Open-market purchase	+12,000	$2.65	$31,800
Jun 20, 2023	Robert Michael Dudley Director, Officer (Chief Executive Officer)	Open-market purchase	+6,607	$2.55	$16,848
Jun 9, 2023	Robert Michael Dudley Director, Officer (Chief Executive Officer)	Open-market purchase	+19,000	$2.76	$52,440

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about TransCode Therapeutics Inc.

Who is the CEO of TransCode Therapeutics Inc.?

Robert Michael Dudley is TransCode Therapeutics Inc.'s Chief Executive Officer.

How many directors are on TransCode Therapeutics Inc.'s board?

TransCode Therapeutics Inc.'s board has 7 directors: Elizabeth Czerepak, Erik Manting, Jack E. Stover, Magda Marquet, Philippe Calais, Robert Michael Dudley and Thomas A. Fitzgerald.

How is TransCode Therapeutics Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="transcode-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.